DD235638A5 - Neue neuromuskulaere blockierungsmittel - Google Patents

Neue neuromuskulaere blockierungsmittel Download PDF

Info

Publication number: DD235638A5
Authority: DD; German Democratic Republic
Prior art keywords: compound; formula; compounds; item; configuration
Prior art date: 1984-07-18

Application number

DD85278691A

Other languages

German (de)

English (en)

Inventor

Roy A Swaringen Jr

Hassan A El-Sayad

David A Yeowell

John J Savarese

Original Assignee

��@��@��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-07-18

Filing date

1985-07-17

Publication date

1986-05-14

1985-07-17 Application filed by ��@��@��@��k�� filed Critical ��@��@��@��k��

1986-05-14 Publication of DD235638A5 publication Critical patent/DD235638A5/de

Links

230000002232 neuromuscular Effects 0.000 title description 5
150000001450 anions Chemical group 0.000 claims abstract description 10
150000001875 compounds Chemical class 0.000 claims description 98
239000000460 chlorine Substances 0.000 claims description 21
238000000034 method Methods 0.000 claims description 17
238000002360 preparation method Methods 0.000 claims description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 14
-1 7-Carboxyheptanoyl Chemical group 0.000 claims description 7
230000008878 coupling Effects 0.000 claims description 5
238000010168 coupling process Methods 0.000 claims description 5
238000005859 coupling reaction Methods 0.000 claims description 5
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
229910052794 bromium Inorganic materials 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
229910052801 chlorine Inorganic materials 0.000 claims description 4
229940125904 compound 1 Drugs 0.000 claims description 4
QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical group ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims description 3
GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
101150065749 Churc1 gene Proteins 0.000 claims description 2
102100038239 Protein Churchill Human genes 0.000 claims description 2
125000001309 chloro group Chemical group Cl* 0.000 claims description 2
229910052740 iodine Inorganic materials 0.000 claims description 2
239000011630 iodine Chemical group 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 claims description 2
125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
239000000842 neuromuscular blocking agent Substances 0.000 abstract description 10
238000001356 surgical procedure Methods 0.000 abstract description 5
239000003158 myorelaxant agent Substances 0.000 abstract 1
229940125706 skeletal muscle relaxant agent Drugs 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
230000002999 depolarising effect Effects 0.000 description 20
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
239000003795 chemical substances by application Substances 0.000 description 19
239000000203 mixture Substances 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
238000004128 high performance liquid chromatography Methods 0.000 description 17
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
239000007787 solid Substances 0.000 description 15
239000000243 solution Substances 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
230000000694 effects Effects 0.000 description 12
150000003839 salts Chemical class 0.000 description 11
239000002904 solvent Substances 0.000 description 11
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical group [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
230000009471 action Effects 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
241000124008 Mammalia Species 0.000 description 7
239000003921 oil Substances 0.000 description 7
235000019198 oils Nutrition 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
229940126062 Compound A Drugs 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 6
241000282412 Homo Species 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000006260 foam Substances 0.000 description 6
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 5
125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 description 5
241000282693 Cercopithecidae Species 0.000 description 5
241000282326 Felis catus Species 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
206010021118 Hypotonia Diseases 0.000 description 5
206010029315 Neuromuscular blockade Diseases 0.000 description 5
150000005690 diesters Chemical class 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
230000036640 muscle relaxation Effects 0.000 description 5
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
CQVWOJSAGPFDQL-UHFFFAOYSA-N 3-iodopropan-1-ol Chemical compound OCCCI CQVWOJSAGPFDQL-UHFFFAOYSA-N 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
150000004694 iodide salts Chemical group 0.000 description 4
AWJUIBRHMBBTKR-UHFFFAOYSA-O isoquinolin-2-ium Chemical compound C1=[NH+]C=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-O 0.000 description 4
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 4
229940032712 succinylcholine Drugs 0.000 description 4
239000000725 suspension Substances 0.000 description 4
ALQIPWOCCJXSKZ-QGZVFWFLSA-N (1r)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1h-isoquinoline Chemical compound C([C@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC(OC)=C(OC)C(OC)=C1 ALQIPWOCCJXSKZ-QGZVFWFLSA-N 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
206010033799 Paralysis Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
229910000147 aluminium phosphate Inorganic materials 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
150000003841 chloride salts Chemical class 0.000 description 3
239000000544 cholinesterase inhibitor Substances 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
239000013078 crystal Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical group C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
235000009518 sodium iodide Nutrition 0.000 description 3
210000003437 trachea Anatomy 0.000 description 3
238000002627 tracheal intubation Methods 0.000 description 3
238000011282 treatment Methods 0.000 description 3
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
PTAPBGKYBVWNJY-UHFFFAOYSA-N 2,3-dibenzoyl-2,3-dihydroxybutanedioic acid;hydrate Chemical compound O.C=1C=CC=CC=1C(=O)C(O)(C(O)=O)C(O)(C(=O)O)C(=O)C1=CC=CC=C1 PTAPBGKYBVWNJY-UHFFFAOYSA-N 0.000 description 2
LAMUXTNQCICZQX-UHFFFAOYSA-N 3-chloropropan-1-ol Chemical compound OCCCCl LAMUXTNQCICZQX-UHFFFAOYSA-N 0.000 description 2
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
ALQIPWOCCJXSKZ-UHFFFAOYSA-N 6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1h-isoquinoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C)C1CC1=CC(OC)=C(OC)C(OC)=C1 ALQIPWOCCJXSKZ-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241000282560 Macaca mulatta Species 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
150000001805 chlorine compounds Chemical group 0.000 description 2
239000002026 chloroform extract Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
229940093499 ethyl acetate Drugs 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
239000003456 ion exchange resin Substances 0.000 description 2
229920003303 ion-exchange polymer Polymers 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229960005457 pancuronium Drugs 0.000 description 2
GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000003421 short acting drug Substances 0.000 description 2
210000002027 skeletal muscle Anatomy 0.000 description 2
241000894007 species Species 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229960001844 tubocurarine Drugs 0.000 description 2
JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 2
239000003643 water by type Substances 0.000 description 2
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
SHCUVJVACNVUPK-UHFFFAOYSA-M 2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium;iodide Chemical compound [I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC SHCUVJVACNVUPK-UHFFFAOYSA-M 0.000 description 1
206010000087 Abdominal pain upper Diseases 0.000 description 1
208000021959 Abnormal metabolism Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
YXSLJKQTIDHPOT-UHFFFAOYSA-N Atracurium Dibesylate Chemical compound C1=C(OC)C(OC)=CC=C1CC1[N+](CCC(=O)OCCCCCOC(=O)CC[N+]2(C)C(C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-UHFFFAOYSA-N 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010062530 Increased bronchial secretion Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
206010028347 Muscle twitching Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
101150052863 THY1 gene Proteins 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229960001862 atracurium Drugs 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
208000006218 bradycardia Diseases 0.000 description 1
230000036471 bradycardia Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229950000405 decamethonium Drugs 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229960003748 edrophonium Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229960003054 gallamine Drugs 0.000 description 1
ICLWTJIMXVISSR-UHFFFAOYSA-N gallamine Chemical compound CCN(CC)CCOC1=CC=CC(OCCN(CC)CC)=C1OCCN(CC)CC ICLWTJIMXVISSR-UHFFFAOYSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000003983 inhalation anesthetic agent Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
GHESMRYCQSFSSF-UHFFFAOYSA-N isoquinolin-2-ium;iodide Chemical compound [I-].C1=[NH+]C=CC2=CC=CC=C21 GHESMRYCQSFSSF-UHFFFAOYSA-N 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000003509 long acting drug Substances 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000006371 metabolic abnormality Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
230000003387 muscular Effects 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
229960002362 neostigmine Drugs 0.000 description 1
LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
IRUCBBFNLDIMIK-UHFFFAOYSA-N oct-4-ene Chemical compound CCCC=CCCC IRUCBBFNLDIMIK-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
208000021090 palsy Diseases 0.000 description 1
238000005192 partition Methods 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
210000004345 peroneal nerve Anatomy 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
230000012232 skeletal muscle contraction Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
229960003279 thiopental Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
125000001701 trimethoxybenzyl group Chemical group 0.000 description 1
HLXQFVXURMXRPU-UHFFFAOYSA-L trimethyl-[10-(trimethylazaniumyl)decyl]azanium;dibromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C HLXQFVXURMXRPU-UHFFFAOYSA-L 0.000 description 1
229960003819 vecuronium Drugs 0.000 description 1
BGSZAXLLHYERSY-XQIGCQGXSA-N vecuronium Chemical compound N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 BGSZAXLLHYERSY-XQIGCQGXSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Jib Cranes (AREA)
Superconductors And Manufacturing Methods Therefor (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Meat, Egg Or Seafood Products (AREA)
Fats And Perfumes (AREA)
Cosmetics (AREA)
Cephalosporin Compounds (AREA)

DD85278691A 1984-07-18 1985-07-17 Neue neuromuskulaere blockierungsmittel DD235638A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB848418303A GB8418303D0 (en)	1984-07-18	1984-07-18	Compounds

Publications (1)

Publication Number	Publication Date
DD235638A5 true DD235638A5 (de)	1986-05-14

Family

ID=10564058

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD85278691A DD235638A5 (de)	1984-07-18	1985-07-17	Neue neuromuskulaere blockierungsmittel

Country Status (30)

Country	Link
US (1)	US4761418A (fr)
EP (1)	EP0181055B1 (fr)
JP (1)	JPH0662568B2 (fr)
AT (1)	ATE60759T1 (fr)
AU (1)	AU574481B2 (fr)
BG (1)	BG60411B2 (fr)
CA (1)	CA1273341A (fr)
CY (1)	CY1687A (fr)
DD (1)	DD235638A5 (fr)
DE (2)	DE19675039I2 (fr)
DK (1)	DK168093B1 (fr)
ES (1)	ES8609260A1 (fr)
FI (1)	FI85019C (fr)
GB (1)	GB8418303D0 (fr)
GE (1)	GEP19960468B (fr)
HK (1)	HK47593A (fr)
HU (1)	HU193996B (fr)
IE (1)	IE58138B1 (fr)
IL (1)	IL75833A (fr)
LT (1)	LT2078B (fr)
LU (1)	LU88801I2 (fr)
LV (1)	LV5483A3 (fr)
MC (1)	MC1690A1 (fr)
MX (1)	MX9203667A (fr)
NL (1)	NL940023I2 (fr)
NZ (1)	NZ212766A (fr)
PL (1)	PL146066B1 (fr)
SG (1)	SG3493G (fr)
SU (1)	SU1468414A3 (fr)
ZA (1)	ZA855407B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5453510A (en) *	1990-07-13	1995-09-26	Burroughs Wellcome Co.	Neuromuscular blocking agents
US5240939A (en) *	1991-10-31	1993-08-31	Anaquest, Inc.	Nitrogen bridge tetrahydroisoquinolines
US5510355A (en) *	1994-09-06	1996-04-23	Bencherif; Merouane	Depolarizing skeletal muscle relaxants
AP1797A (en) *	1997-03-25	2007-11-15	Avera Pharmaceuticals Inc	Substituted isoquinolines as ultra short acting neuromuscular blockers.
GB0204087D0 (en) *	2002-02-21	2002-04-10	Legislator 1563 Ltd	Di-ester derivatives as short acting neuromuscular blockers
WO2005041960A2 (fr) *	2003-10-28	2005-05-12	Cornell Research Foundation, Inc.	Agents de blocage neuromusculaires et leurs antagonistes
US7872137B2 (en) *	2006-06-20	2011-01-18	Farmabios S.P.A.	Process for the preparation of mivacurium chloride
WO2008070121A1 (fr) *	2006-12-06	2008-06-12	Cornell Research Foundation, Inc.	Agents de blocage neuromusculaire à durée intermédiaire, et leurs antagonistes
EP2125742A2 (fr) *	2007-03-08	2009-12-02	Chemagis Ltd.	Procédé de séparation de sels (1r,1'r)-atracurium
EP2125743A1 (fr) *	2007-03-26	2009-12-02	Chemagis Ltd.	Procédé de séparation de sels de (1r, 1'r)-atracurium
BRPI0809893A2 (pt) *	2007-05-01	2014-09-30	Chemagis Ltd	Processo para prepar um sal de (1r-cis) - [(3,4 - dimetoxifenil) metil] - 1, 2,3,4 - tetraidro - 6,7 - dimetoxi - 2 - metil - 2 - carboxietil - isoquinolínio"
CA2685488A1 (fr) *	2007-05-01	2008-11-06	Chemagis Ltd.	Nouveaux composes d'isoquinolinium utiles dans la preparation de cisatracurium et intermediaires associes
WO2008155752A1 (fr) *	2007-06-18	2008-12-24	Chemagis Ltd.	Procédé de séparation de sels de (1r,1'r)-atracurium
CA2692636A1 (fr) *	2007-07-09	2009-01-15	Chemagis Ltd.	Procede de fabrication de cisatracurium et d'intermediaires associes
AU2008320380A1 (en) *	2007-10-29	2009-05-07	Chemagis Ltd.	Novel R,R'-atracurium salts
ITMI20080319A1 (it)	2008-02-28	2009-08-29	Recordati Chem Pharm	Processo per la risoluzione di derivati isochinolinici
AU2009241211A1 (en) *	2008-05-01	2009-11-05	Chemagis Ltd.	Cisatracurium derivatives, preparation and uses thereof
WO2010107488A1 (fr)	2009-03-17	2010-09-23	Cornell University	Agents de blocage neuromusculaires non dépolarisants réversibles et leur méthode
US9220700B2 (en)	2009-08-19	2015-12-29	Cornell University	Cysteine for physiological injection
WO2013021398A2 (fr) *	2011-08-05	2013-02-14	Sequent Scientific Limited	Procédé de préparation du chlorure de mivacurium
ES2625329T3 (es)	2012-06-29	2017-07-19	Cornell University	Agentes bloqueantes neuromusculares asimétricos reversibles de duración ultra-corta, corta o intermedia
CN103373959A (zh) *	2013-06-14	2013-10-30	安徽省先锋制药有限公司	顺式苄基异喹啉类化合物的制备方法及其用途
CN107782821B (zh) *	2016-08-26	2021-11-09	四川科瑞德制药股份有限公司	一种神经肌肉阻滞剂的分析方法
CN107778237A (zh) *	2016-08-26	2018-03-09	四川科瑞德制药股份有限公司	一种神经肌肉阻滞剂中间体的新晶型及其制备方法和用途
CN108938573B (zh) *	2017-05-26	2021-08-10	四川科瑞德制药股份有限公司	一种神经肌肉阻滞剂组合物及其制备方法和用途
CN108503564A (zh) *	2017-09-30	2018-09-07	武汉嘉诺康医药技术有限公司	一种米库氯铵中间体及利用该中间体合成米库氯铵的方法
CN110361472B (zh) *	2019-07-29	2022-04-29	武汉嘉诺康医药技术有限公司	一种米库氯铵中间体miv-g异构体的hplc检测方法
CN111004179B (zh) *	2019-11-11	2021-03-09	武汉大安制药有限公司	一种5’-甲氧基劳丹素的拆分方法
WO2025140288A1 (fr) *	2023-12-25	2025-07-03	上海森辉医药有限公司	Tétrahydroisoquinoléine et son utilisation pharmaceutique

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB863717A (en) *	1958-07-03	1961-03-22	Allen & Hanburys Ltd	Tetrahydropapaverine derivatives and their preparation
US3004031A (en) *	1958-07-03	1961-10-10	Allen & Hauburys Ltd	Diquaternary salts of papaverino esters
AU506657B2 (en) *	1975-12-10	1980-01-17	Wellcome Foundation Limited, The	Isoquinoline derivatives
ZA784331B (en) *	1977-08-01	1979-12-27	Massachusetts Gen Hospital	Neuromuscular blocking agents
US4192877A (en) *	1977-08-01	1980-03-11	Massachusetts General Hospital	Neuromuscular blocking agents
CA1125287A (fr) *	1978-07-21	1982-06-08	John J. Savarese	Modes d'emploi de substances a base de bis-isoquinolinium
US4235906A (en) *	1978-07-21	1980-11-25	Massachusetts General Hospital	Bis-isoquinolinium compounds, compositions and methods of use
CA1153380A (fr) *	1979-10-19	1983-09-06	Hassan A. El-Sayad	Sels de tetrahydroisoquinolinium, agents de blocage neuromusculaire
US4491665A (en) *	1979-10-19	1985-01-01	Burroughs Wellcome Co.	Method of preparing isomers of bis isoquinolinium compounds
EP0054309B1 (fr) *	1980-12-17	1984-08-22	The Wellcome Foundation Limited	Bloqueurs neuromusculaires à action prolongée, compositions pharmaceutiques les contenant et leurs procédés de préparation
JPS5899465A (ja) *	1981-11-23	1983-06-13	ザ・ウエルカム・フアウンデ−シヨン・リミテツド	イソキノリン誘導体

1984
- 1984-07-18 GB GB848418303A patent/GB8418303D0/en active Pending
1985
- 1985-07-11 PL PL1985254571A patent/PL146066B1/pl unknown
- 1985-07-17 IE IE179185A patent/IE58138B1/en not_active IP Right Cessation
- 1985-07-17 US US06/756,025 patent/US4761418A/en not_active Expired - Lifetime
- 1985-07-17 ES ES545319A patent/ES8609260A1/es not_active Expired
- 1985-07-17 LU LU88801C patent/LU88801I2/fr unknown
- 1985-07-17 FI FI852807A patent/FI85019C/fi not_active IP Right Cessation
- 1985-07-17 EP EP85305097A patent/EP0181055B1/fr not_active Expired - Lifetime
- 1985-07-17 NZ NZ212766A patent/NZ212766A/en unknown
- 1985-07-17 DK DK324985A patent/DK168093B1/da not_active IP Right Cessation
- 1985-07-17 ZA ZA855407A patent/ZA855407B/xx unknown
- 1985-07-17 HU HU852745A patent/HU193996B/hu unknown
- 1985-07-17 MC MC851781A patent/MC1690A1/fr unknown
- 1985-07-17 AT AT85305097T patent/ATE60759T1/de active
- 1985-07-17 DE DE1996175039 patent/DE19675039I2/de active Active
- 1985-07-17 JP JP60157963A patent/JPH0662568B2/ja not_active Expired - Lifetime
- 1985-07-17 SU SU853926201A patent/SU1468414A3/ru active
- 1985-07-17 DE DE8585305097T patent/DE3581699D1/de not_active Expired - Lifetime
- 1985-07-17 CA CA000486916A patent/CA1273341A/fr not_active Expired - Lifetime
- 1985-07-17 DD DD85278691A patent/DD235638A5/de unknown
- 1985-07-17 IL IL75833A patent/IL75833A/xx not_active IP Right Cessation
- 1985-07-17 AU AU45108/85A patent/AU574481B2/en not_active Expired
1992
- 1992-06-26 MX MX9203667A patent/MX9203667A/es unknown
1993
- 1993-01-08 SG SG34/93A patent/SG3493G/en unknown
- 1993-03-10 LV LV930178A patent/LV5483A3/xx unknown
- 1993-04-07 LT LTRP478A patent/LT2078B/xx not_active IP Right Cessation
- 1993-05-13 HK HK475/93A patent/HK47593A/en not_active IP Right Cessation
- 1993-09-14 BG BG098109A patent/BG60411B2/bg unknown
- 1993-10-10 CY CY1687A patent/CY1687A/xx unknown
- 1993-12-06 GE GEAP19931677A patent/GEP19960468B/en unknown
1994
- 1994-11-18 NL NL940023C patent/NL940023I2/nl unknown

Also Published As

Publication number	Publication date
SG3493G (en)	1993-03-12
AU4510885A (en)	1986-01-23
NZ212766A (en)	1988-03-30
ES8609260A1 (es)	1986-09-01
DE3581699D1 (de)	1991-03-14
DK168093B1 (da)	1994-02-07
AU574481B2 (en)	1988-07-07
FI852807L (fi)	1986-01-19
FI85019C (fi)	1992-02-25
NL940023I2 (nl)	1998-06-02
NL940023I1 (nl)	1995-01-02
PL254571A1 (en)	1986-07-15
FI85019B (fi)	1991-11-15
EP0181055B1 (fr)	1991-02-06
US4761418A (en)	1988-08-02
JPH0662568B2 (ja)	1994-08-17
ZA855407B (en)	1986-04-30
PL146066B1 (en)	1988-12-31
GEP19960468B (en)	1996-08-29
GB8418303D0 (en)	1984-08-22
CY1687A (en)	1993-10-10
JPS6187666A (ja)	1986-05-06
HU193996B (en)	1987-12-28
LV5483A3 (lv)	1994-03-10
MC1690A1 (fr)	1986-07-18
IL75833A0 (en)	1985-11-29
FI852807A0 (fi)	1985-07-17
DE19675039I2 (de)	2003-01-09
HUT40626A (en)	1987-01-28
MX9203667A (es)	1992-07-31
BG60411B2 (bg)	1995-02-28
IE851791L (en)	1986-01-18
LU88801I2 (fr)	1996-11-05
IE58138B1 (en)	1993-07-14
LT2078B (lt)	1993-06-15
ATE60759T1 (de)	1991-02-15
EP0181055A1 (fr)	1986-05-14
DK324985A (da)	1986-01-19
ES545319A0 (es)	1986-09-01
IL75833A (en)	1988-11-30
CA1273341A (fr)	1990-08-28
DK324985D0 (da)	1985-07-17
SU1468414A3 (ru)	1989-03-23
HK47593A (en)	1993-05-21

Legal Events

Date	Code	Title	Description
2004-04-28	IF04	In force in the year 2004	Expiry date: 20050718

Publication	Publication Date	Title
DD235638A5 (de)	1986-05-14	Neue neuromuskulaere blockierungsmittel
DE69830157T2 (de)	2006-05-11	Substituierte isochinoline als ultrakurz wirkende neuromuskuläre blocker
DE69119768T2 (de)	1996-10-02	Neuromuskuläre blocker
DE3010153C2 (fr)	1989-08-24
CH626345A5 (fr)	1981-11-13
DE1911464B2 (de)	1975-02-27	3,4-Dihydroisochinoline, Verfahren zu ihrer Herstellung und Arzneimittel
DE2113866C3 (de)	1981-10-15	(+-)-12-Oxo-2,3,5,6,12,13,13a,13boctahydro-1H-indolo[3,2,1-d,e]pyrido[3,2,1-i,j][1,5]naphthyridin, dessen Enantiomere und Salze, ein Verfahren zur Herstellung dieser Verbindung und diese Verbindungen enthaltende Arzneimitel
DE3546218A1 (de)	1987-07-02	Azoniaspironortropanolester, verfahren zu deren herstellung und pharmazeutisches mittel
DE3204960A1 (de)	1983-08-25	Corynanthein-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3226921C2 (de)	1994-03-10	Neue 3,7-Diazabicyclo[3.3.1]nonan Verbindungen und Verfahren zu ihrer Herstellung
DE2632118A1 (de)	1977-01-20	Apovincaminolester und verfahren zu deren herstellung
DE3804936A1 (de)	1988-09-01	Piperazincarbonsaeure, ihre herstellung und diese enthaltende arzneimittel
DE3000625A1 (de)	1980-07-17	Cis- und trans-isomere von 3-aryloxy- 4-hydroxypyrrolidinen und deren derivaten, verfahren zu ihrer herstellung und ihre verwendung
DE68924545T2 (de)	1996-03-21	Verwendung von Chinolizin- und Chinolizinon-Derivaten zur Herstellung von Arzneimitteln.
CH668262A5 (de)	1988-12-15	(-)-1beta-aethyl-1alpha-(hydroxymethyl)-1,2,3,4,6,7,12,12balpha-octahydroindolo(2,3-a)chinolizin und verfahren zu seiner herstellung.
EP0353754B1 (fr)	1992-12-02	Dérivés de benzodiazepines radioactivement marqués
DE2002107A1 (de)	1970-07-30	Neue organische Verbindungen und Verfahren zu deren Herstellung
DD210044A5 (de)	1984-05-30	Verfahren zur herstellung von trans-4ar-5-n-propyl-4,4a,5,6,7,8,8a,9-octahydro-1h(und 2h)pyrazolo(3,4-g)-chinolinen
DE3046017C2 (de)	1986-09-25	Indolizin-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzung
AT379810B (de)	1986-03-10	Verfahren zur herstellung von neuen 3,7-diazabicyclo (3,3,1) nonanderivaten, deren stereoisomeren und physiologisch vertraeglichen saeureadditionssalzen
DE2421999C3 (de)	1976-12-16	Vincaminsäurederivate
DE1620407C (de)	1973-05-24	3 Hydroxy 6 oxo-N phenylathyl morphinan (eis) verbindungen und ihre Salze sowie Verfahren zu deren Her stellung
CH626893A5 (en)	1981-12-15	Process for the preparation of pyrrolo[2,1-b]-3-benzazepines
DE2014860C3 (de)	1977-11-03	Phenothiazinderivate, deren Herstellung und pharmazeutische Zusammensetzungen
DE3501225A1 (de)	1986-07-24	Spirodioxolane, ihre herstellung und verwendung